nedaplatin has been researched along with Ascites in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Ding, Y; Ma, L; Zhang, L; Zhuang, Y | 1 |
| Li, S; Lu, H; Sun, K; Taylor, EW; Wan, X; Wang, D; Wang, Y; Zhang, J | 1 |
2 other study(ies) available for nedaplatin and Ascites
| Article | Year |
|---|---|
A rare case report of ovarian juvenile granulosa cell tumor with massive ascites as the first sign, and review of literature: Case report and review of literature.
Topics: Abdominal Cavity; Antineoplastic Agents; Ascites; CA-125 Antigen; Chemotherapy, Adjuvant; Female; Granulosa Cell Tumor; Humans; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salpingo-oophorectomy; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult | 2018 |
Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Buthionine Sulfoximine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; Glutathione; Liver Neoplasms, Experimental; Male; Mice; Organoplatinum Compounds; Random Allocation; Thioredoxin-Disulfide Reductase | 2012 |